Comparative efficacy of two microdoses of a potentized homeopathic drug, arsenicum album, to ameliorate toxicity induced by repeated sublethal injections of arsenic trioxide in mice

Pathobiology

Volumn 75, Issue 3, 2008, Pages 156-170

  Banerjee, Pathikrit ^a   Bhattacharyya, Soumya Sundar ^a   Pathak, Surajit ^a   Naoual, Boujedaini ^b   Belon, Philippe ^b   Khuda Bukhsh, Anisur Rahman ^a  

^a UNIVERSITY OF KALYANI   (India)

^b Boiron   (France)

Author keywords

Arsenic toxicity; Biomarkers; Homeopathy; Matrix metalloproteinase; Mice

Indexed keywords

ACID PHOSPHATASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; CATALASE; ESTRADIOL; GLUTATHIONE; SUCCINATE DEHYDROGENASE; TESTOSTERONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HOMEOPATHY; LIPID PEROXIDATION; MALE; MICRONUCLEUS; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPERMATOZOON;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; ARSENIC POISONING; ARSENICALS; CATALASE; CHROMOSOME ABERRATIONS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUTATHIONE; LIPID METABOLISM; MALE; MATERIA MEDICA; MICE; MITOTIC INDEX; OXIDES; SPERMATOZOA; SUCCINATE DEHYDROGENASE; TRANSAMINASES; TREATMENT OUTCOME;

MUS; MUS MUSCULUS;

EID: 48749092565     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000124976     Document Type: Article

References (41)

1. Rahman M, Tondel M, Ahmad SA: Hypertension and arsenic exposure in Bangladesh. Hypertension 1999;33:74-78.
2. Engel RR, Smith AH: Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health 1994;49:418-427.
3. Wu MM, Kuo TL, Hwang YH, Chen CJ: Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-1132.
4. Hu H: Exposure to metals. Prim Care 2000;27:983-996.
5. Chen CJ, Wang CJ: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 1990;50:5470-5474.
6. International Programme on Chemical Safety: Inorganic Arsenic Compounds Other than Arsine. Health and Safety Guide No. 70. Geneva, World Health Organization, 1992.
7. International Programme on Chemical Safety: Environmental Health Criteria Document 224: Arsenic and Arsenic Compounds. Geneva, World Health Organization, 2001.
8. International Agency for Research on Cancer: Summaries and Evaluations: Arsenic and Arsenic Compounds. Lyon, International Agency for Research on Cancer, 1987.
9. Department for Environment Food and Rural Affairs, Environment Agency: Contaminants in Soil: Collation of Toxicological Data and Intake Values for Humans. Arsenic. Bristol, Environment Agency, 2002.
10. Tchounwou PB, Wilson BA, Ishaque A: Important considerations in the development of public health advisories for arsenic and arsenic containing compounds in drinking water. Rev Environ Health 1999;14:1-19.
11. National Academy of Sciences: Arsenic. Washington, National Academy of Sciences, 1977.
12. Overall evaluation of carcinogenicity: an update of IARC monographs. IARC Monogr Eval Carcinog Risks Hum 1989;47: 1-42.
13. Mitra K, Kundu SN, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing toxic effects produced by arsenic trioxide in mice: I. On the rate of accumulation of arsenic in certain vital organs. Complement Ther Med 1998;6:178-184.
14. Mitra K, Kundu SN, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing toxic effects produced by arsenic trioxide in mice: II. On alterations of body weight, tissue weight and total protein. Complement Ther Med 1999;7:24-34.
15. Kundu SN, Mitra K, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: III. Enzymatic changes and recovery of tissue damage in liver. Complement Ther Med 2000;8:76-81.
16. Kundu SN, Mitra K, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: IV. Pathological changes, protein profiles and content of DNA and RNA. Complement Ther Med 2000;8:157-175.
17. Datta S, Mallick P, Khuda-Bukhsh AR: Efficacy of a potentized homeopathic drug (arsenicum album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdoses. Complement Ther Med 1999;7:62-75.
18. Mallick P, Chakrabarti Mallick J, Guha B, Khuda-Bukhsh AR: Ameliorating effect of microdoses of a potentized homeopathic drug, arsenicum album, on arsenic induced toxicity in mice. BMC Complement Altern Med 2003;3:1-19.
19. Pathak S, Das JK, Biswas SJ, Khuda-Bukhsh AR: Protective potentials of a potentized homeopathic drug, Lycopodium-30, in ameliorating azo dye induced hepatocarcinogenesis in mice. Mol Cell Biochem 2006;258:121-131.
20. Biswas SJ, Pathak S, Khuda-Bukhsh AR: Assessment of the genotoxic and cytotoxic potential of an antiepileptic drug phenobarbital, in mice: a time course study. Mutat Res 2004;563:1-11.
21. Pathak S, Bhattacharjee N, Das JK, Choudhury SC, Karmakar SR, Banerjee P, Paul S, Banerjee A, Khuda-Bukhsh AR: Supportive evidence for the anticancerous potential of alternative medicine against hepatocarcinogenesis in mice. Forsch Komplement Med (2006) 2007;14:148-156.
22. Billings PC, Habres JM, Liao DC, Tuttle SW: Human fibroblasts contain a proteolytic activity, which is inhibited by the Bowman-Birk protease inhibitor. Cancer Res 1991;51:5539-5543.
23. Locke J: The determination of eight elements in human liver tissue by flame atomic absorption spectrometry in sulphuric acid solution. Anal Chem Acta 1979;104:225-231.
24. Nurenberg WH: Voltametric trace analysis in ecological chemistry of toxic metals. Pure Appl Chem 1982;54:853-878.
25. Fisher RA, Yates F: Statistical Tables for Biological, Agricultural and Medical Research. Edinburgh, Oliver and Boyd, 1963.
26. Pi JB, Yamauchi H, Kumagai Y: Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 2002;110:331-336.
27. Flora SJS: Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 1999;26:865-869.
28. Maiti S, Chatterjee AK: Effects on levels of glutathione and some related enzymes in tissues after an acute arsenic exposure in rats and their relationship to dietary protein deficiency. Arch Toxicol 2001;75:531-537.
29. Guha Mazumder DN, Das Gupta J, Santra A, Pal A, Ghose A, Sarkar S, Chattopadhaya N, Chakraborti D: Non-cancer effects of chronic arsenicosis with special reference to liver damage;in Aberthy CO, Calderon RL, Chappel WR (eds): Arsenic: Exposure and Health Effects. London, Chapman and Hall, 1997, pp 113-123.
30. Sternlicht MD, Werb Z: How matrix metalloproteases regulate cell behaviour. Annu Rev Cell Dev Biol 2001;17:463-516.
31. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
32. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling (review). Trends Genet 1990;6:121-125.
33. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
34. Lee AY, Akers KT, Collier M, Li L, Eisen AZ, Seltzer JL: Intracellular activation of gelatinase A (72-kDa type IV collagenase) by normal fibroblasts. Proc Natl Acad Sci USA 1997;94:4424-4429.
35. Seltzer JL, Lee AY, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ: Activation of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res 1994;213:365-374.
36. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
37. Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tissue invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-2072.
38. Wang Z, Juttermann R, Soloway PD: TIMP-2 is required for efficient activation of pro-MMP-2 in vivo. J Biol Chem 2000;275:26411-26415.
39. Khuda-Bukhsh AR: Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo. Complement Ther Med 1997;5:43-46.
40. Khuda-Bukhsh AR: Towards understanding molecular mechanisms of action of homeopathic drugs: an overview. Mol Cell Biochem 2003;253:339-345.
41. Khuda-Bukhsh AR: Laboratory research in homeopathy: pro. Integr Cancer Ther 2006;5:320-332.